Adverse events in second- and third-line treatments for acute and chronic graft-versus-host disease: systematic review.
Vladica M VelickovicEmily McIlwaineRongrong ZhangTimothy SpelmanPublished in: Therapeutic advances in hematology (2020)
The reported incidence of infectious AEs in aGvHD and grade 3-5 AEs in cGvHD was lower on ECP compared with pharmaceutical management.